Print

Chemotherapy for Gastric Cancer: ?Who is an Asian Star??

Issue: Vol.9, No.4 - October 2010

« Back to Articles

Article Type: Manuscript

Download PDF Version »

  1. Dr Fumio Nagashima
    Department of Medical Oncology, Comprehensive Cancer Center, Saitama Medical University,rn
  2. Ken-Ichi Fujita
  3. Yasutsuna Sasaki

Gastric cancer (GC) is major health problem worldwide and especially in Asia, the prognosis of unresectable or recurrent GC is poor. Recent phase III studies demonstrate survival benefit of chemotherapy for unresectable or recurrent GC. Several new agents, including S-1, capecitabine, docetaxel, paclitaxel, and irinotecan have promising effects for GC. The JCOG9912 trial revealed non-inferiority of S-1 was statistically significant. S-1 is also promising for GC in adjuvant setting. From these results, S-1 is considered to be a key-drug for treatment of GC in Japan. Based on biomarker analysis for patients with GC receiving chemotherapy, a translational research of biomarker is ongoing for patients enrolled in JCOG9912 trial. Pharmacogenetic studies provide pivotal information for cancer patients. UGT1A1*28 polymorphism has been considered to be important for predicting severe neutropenia in patients receiving irinotecan based chemotherapy. In Asian population, UGT1A1*6 is also reported to be important. We need strong collaborative network for developing new treatment strategy for GC.

Download PDF Version »

Favourites   Share / Bookmark

Also In This Issue

« Back to Articles